PAP
APRE icon

Persistent Asset Partners’s Aprea Therapeutics APRE Stock Holding History

Persistent Asset Partners’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.22K Buy
+11,490
New +$9.59K ﹤0.01% 742

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Persistent Asset Partners's APRE Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Aprea Therapeutics (APRE) in Q2 2026: 11,490 shares worth $9.22K. The stake represents ﹤0.01% of the portfolio and ranks #742 among its holdings.

6 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • Persistent Asset Partners held 11,490 shares of Aprea Therapeutics worth $9.22K as of Q2 2026.
  • Aprea Therapeutics was a new Persistent Asset Partners position in Q2 2026.
  • Aprea Therapeutics made up ﹤0.01% of Persistent Asset Partners's portfolio in Q2 2026, its #742 holding.
  • 6 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.